AMLX
Amylyx Pharmaceuticals, Inc.
$35.11
+13.68
(+63.84%)
Mkt Cap
3.90B
Volume
23,599,890
52W Range
7.63-35.39
Sector
Healthcare
Beta
-0.20
EPS (TTM)
-1.41 USD
P/E Ratio
-7.90
Revenue (TTM)
0 USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 87.37M | 380.79M | 22.23M | 0 | 650,000 | 1.43M |
| Net Income | (144.74M) | (301.74M) | 49.27M | (198.38M) | (87.93M) | (42.28M) | (14.82M) |
| EPS | -1.53 | -4.43 | 0.73 | -2.98 | -1.52 | -0.79 | -0.26 |
| Free Cash Flow | (123.48M) | (167.80M) | 10.68M | (182.40M) | (75.15M) | (36.85M) | (10.69M) |
| FCF / Share | -1.31 | -2.46 | 0.16 | -2.74 | -1.30 | -0.65 | -0.19 |
| Operating CF | (123.34M) | (167.65M) | 11.92M | (179.87M) | (74.80M) | (36.70M) | (10.69M) |
| Total Assets | 332.64M | 193.63M | 517.45M | 391.45M | 105.61M | 14.10M | 3.22M |
| Total Debt | 5.96M | 1.98M | 4.24M | 6.28M | 0 | 1.43M | 14.93M |
| Cash & Equiv | 226.65M | 77.39M | 170.20M | 62.53M | 50.19M | 12.88M | 3.06M |
| Book Value | 305.26M | 164.76M | 433.43M | 340.61M | (151.17M) | (66.72M) | (25.36M) |
| Return on Equity | -0.47 | -1.83 | 0.11 | -0.58 | N/A | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | (665,000) | 416,000 | (1.02M) | 88.64M | 108.45M | 102.69M |
| Net Income | (43.42M) | (41.28M) | (33.00M) | (34.39M) | (41.44M) | (35.91M) | (37.55M) | (72.70M) | (72.70M) | (118.79M) | 4.73M | 20.89M |
| EPS | -0.39 | -0.37 | -0.28 | -0.37 | -0.46 | -0.42 | -0.55 | -1.07 | -1.07 | -1.75 | 0.07 | 0.31 |
| Free Cash Flow | (31.45M) | (36.88M) | (27.99M) | (30.39M) | (25.27M) | (39.84M) | (59.03M) | (41.55M) | (66.67M) | (556,000) | 13.20M | (5.53M) |
| FCF / Share | -0.28 | -0.33 | -0.30 | -0.33 | -0.28 | -0.46 | -0.86 | -0.61 | -0.98 | -0.01 | 0.20 | -0.08 |
| Operating CF | (31.42M) | (36.88M) | (27.90M) | (30.37M) | (25.25M) | (39.82M) | (59.01M) | (41.57M) | (66.58M) | (489,000) | 13.55M | (5.17M) |
| Total Assets | 264.56M | 293.60M | 332.64M | 362.74M | 194.60M | 219.68M | 193.63M | 250.71M | 332.16M | 417.46M | 517.45M | 466.58M |
| Total Debt | 5.25M | 5.63M | 5.96M | 5.93M | 5.96M | 1.38M | 1.98M | 2.57M | 3.14M | 3.69M | 4.24M | 4.77M |
| Cash & Equiv | 49.33M | 229.14M | 226.65M | 225.18M | 58.09M | 59.76M | 77.39M | 71.84M | 75.00M | 170.55M | 170.20M | 135.26M |
| Book Value | 239.17M | 273.16M | 305.26M | 332.00M | 167.88M | 201.42M | 164.76M | 196.20M | 261.31M | 324.44M | 433.43M | 418.40M |
| Return on Equity | -0.18 | -0.15 | -0.11 | -0.10 | -0.25 | -0.18 | -0.23 | -0.37 | -0.28 | -0.37 | 0.01 | 0.05 |
AMLX News
4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year
Amylyx Pharmaceuticals, Inc. $AMLX Shares Bought by Bank of New York Mellon Corp
Amylyx Pharmaceuticals: Avexitide Defines The Endocrine Rebuild
Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2026 Earnings Call Transcript
Amylyx Pharmaceuticals Q2 Earnings Call Highlights
Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results
Amylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026
Amylyx Pharmaceuticals Eyes Q3 Phase 3 Avexitide Readout as PBH Launch Plans Take Shape